Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls

The Lancet Oncology

Volumn 11, Issue 10, 2010, Pages 992-1000

  Tolmachev, Vladimir ^a   Stone Elander, Sharon ^b,c   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AROMATASE INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; GEFITINIB; IMATINIB; INDIUM 111; LAPATINIB; MONOCLONAL ANTIBODY; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; PANITUMUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; LIGAND; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADVANCED CANCER; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER SURVIVAL; CELL MOTILITY; CELL PROLIFERATION; DIMERIZATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG UPTAKE; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; LUNG ADENOCARCINOMA; METASTASIS; MOLECULAR IMAGING; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC USE; DRUG MONITORING; ENZYMOLOGY; NEOPLASMS; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; LIGANDS; MOLECULAR IMAGING; NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957374838     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70088-7     Document Type: Review

References (77)

1. McGill MA, McGlade CL Cellular signaling. The basic science of oncology 2005, 142-146. McGraw-Hill Companies, New York. 4th edn. I.F. Tannock, R.P. Hill, R.G. Bristow, L. Harrington (Eds.).
2. Zafir-Lavie I, Michaeli Y, Reiter Y Novel antibodies as anticancer agents. Oncogene 2007, 26:3714-3733.
3. 18F-FDG PET. J Nucl Med 2009, 50:97S-105S.
4. Dempke WC, Heinemann V Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009, 45:1117-1128.
5. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. PNAS 2006, 103:5090-5095.
6. Solit DB, Chiosis G Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43.
7. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
8. Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, van Dalen A Tumor markers in breast cancer, EGTM recommendations. Anticancer Res 1999, 19:2785-2820.
9. Ludwig JA, Weinstein JN Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
10. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
11. Dei Tos AP, Ellis I Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. Eur J Cancer 2005, 41:1383-1392.
12. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004, 22:4772-4778.
13. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
14. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994, 70:335-341.
15. Mankoff DA Molecular imaging to select cancer therapy and evaluate treatment response. Q J Nucl Med Mol Imaging 2009, 53:181-192.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Weber WA Assessing tumor response to therapy. J Nucl Med 2009, 50:1S-10S.
18. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11:2785-2808.
19. van den Abbeele AD The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 2008, 13:8-13.
20. 18F-fluorothymidine PET. J Nucl Med 2005, 46:114-120.
21. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007, 67:11463-11469.
22. 18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008, 14:7423-7429.
23. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumor xenografts. Eur J Nucl Med Mol Imaging 2009, 36:81-93.
24. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009, 50:1340-1348.
25. Niu G, Cai W, Chen K, Chen X Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 2008, 10:99-106.
26. 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991, 83:97-104.
27. Behr TM, Béhé M, Wörmann B Trastuzumab and breast cancer. N Engl J Med 2001, 345:995-996.
28. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
29. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981.
30. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008, 35:1857-1867.
31. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48:1313-1319.
32. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009, 50:123-131.
33. 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008, 23:158-171.
34. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
35. 89Zr-trastuzumab in metastatic breast cancer patients. J Clin Oncol 2009, 27:1045.
36. Tolmachev V Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008, 14:2999-3019.
37. 111In-DTPA-trastuzumab. Br J Pharmacol 2004, 143:99-106.
38. Ogawa M, Regino CA, Seidel J, et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 2009, 20:2177-2184.
39. Niu G, Li Z, Xie J, Le QT, Chen X PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009, 50:1116-1123.
40. Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer 2008, 44:1835-1840.
41. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-706.
42. 124I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004, 45:1237-1244.
43. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008, 49:788-795.
44. 18F-FDG PET. J Nucl Med 2006, 47:793-796.
45. 124I-labeled hapten-peptide. J Nucl Med 2006, 47:1678-1688.
46. 18F radiolabeling for PET. J Nucl Med 2009, 50:991-998.
47. 131I-labeled epidermal growth factor. Clin Cancer Res 1996, 2:13-20.
48. Rusckowski M, Qu T, Chang F, Hnatowich DJ Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res 1997, 50:393-401.
49. 111In for imaging human breast cancer. J Nucl Med 2000, 41:903-911.
50. 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005, 46:1881-1888.
51. Blankenberg FG, Backer MV, Levashova Z, Patel V, Backer JM In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 2006, 33:841-848.
52. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006, 47:2048-2056.
53. Chen K, Cai W, Li ZB, Wang H, Chen X Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol 2009, 11:15-22.
54. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008, 122:2310-2314.
55. 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res 1997, 57:2754-2759.
56. Sun BF, Kobayashi H, Le N, et al. Effects of insulinlike growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med 2000, 41:318-326.
57. 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008, 35:645-653.
58. Grönwall C, Ståhl S Engineered affinity proteins-generation and applications. J Biotechnol 2009, 140:254-269.
59. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res 2007, 13:6070-6079.
60. Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007, 22:573-584.
61. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
62. Friedman M, Orlova A, Johansson E, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 2008, 376:1388-1402.
63. 111In-DOTA-Z (EGFR:2377) affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010, 37:613-622.
64. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007, 67:2178-2186.
65. 18F-labeled affibody molecules. J Nucl Med 2009, 50:1131-1139.
66. 68Ga-labeled affibody. J Nucl Med 2010, published online May 19. 10.2967/jnumed.109.073239.
67. 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999, 65:165-174.
68. 11C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imaging 2009, 36:1283-1295.
69. 11C-PD153035 in humans. J Nucl Med 2009, 50:303-308.
70. 11C-PD153035 PET/CT for molecular imaging of EGFR in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008, 26:3503. (abstr).
71. Gelovani JG Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev 2008, 27:645-653.
72. 18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008, 35:1089-1099.
73. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006, 8:262-277.
74. Abourbeh G, Dissoki S, Jacobson O, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 2007, 34:55-70.
75. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009, 69:873-878.
76. 11C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imaging 2009, 36:1283-1295.
77. 124I-Iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med 2010, 51:121-129.